Hemab Therapeutics Holdings, Inc. (COAG) has completed its initial public offering, selling 19,262,500 shares at $18.00 apiece and bringing in roughly $346.7 million in gross proceeds before accounting for underwriting fees and other expenses. The total includes 2,512,500 additional shares issued when underwriters exercised their over-allotment option in full.
The company listed its common stock on the Nasdaq Global Select Market, with trading commencing on May 1, 2026. The offering was managed by a syndicate led by Goldman Sachs & Co. LLC, Jefferies and Evercore ISI as joint book-running managers, with Wedbush PacGrow serving as lead manager.
Hemab is headquartered in Cambridge, Massachusetts, with operations also in Copenhagen. The company focuses on discovering and developing therapies for bleeding and thrombotic disorders. Its publicly disclosed pipeline highlights two clinical-stage antibody programs:
- Sutacimig - described as a bispecific antibody in clinical development for the treatment of Glanzmann thrombasthenia and Factor VII deficiency.
- HMB-002 - characterized as a monovalent antibody being developed for the treatment of Von Willebrand Disease.
The Securities and Exchange Commission declared the registration statement for the offering effective on April 30, 2026, clearing the way for the public sale the following day. The gross proceeds figure reported is before deductions for underwriting fees and other offering-related expenses.
This capital raise provides Hemab with additional resources as it advances its two lead antibody candidates through clinical development. The structure of the offering, which included a full exercise of the underwriters' over-allotment option, resulted in the issuance of the incremental 2,512,500 shares included in the total 19,262,500 shares sold.
Investors, market participants and stakeholders in biotechnology and capital markets will be watching Hemab's use of proceeds and the clinical progress of sutacimig and HMB-002 as the company transitions to a public reporting profile following its Nasdaq listing.